(Tight 6–8 minute read, with source links for deeper exploration.)

Research conducted with Perplexity AI | Content compiled with Claude AI | All sources cited and verified

FDA and EMA issued the first transatlantic AI governance framework for drug development with 10 guiding principles covering lifecycle management, data governance, and traceability—setting concrete expectations for CIO architecture and cross-functional oversight.

Lilly–NVIDIA's $1B co-innovation lab and parallel infrastructure deals (Servier, GSK, Pfizer) validate AI platforms and foundation models as core enterprise infrastructure, forcing build-vs-buy and OT/IT convergence decisions.

Health-ISAC quantified 455 ransomware incidents in 2025 with supply-chain attacks as the primary vector and AI-enabled threats the top 2026 concern, while Oracle/Cerner and vendor breaches exposed gaps in third-party monitoring.

FDA expanded enforcement discretion for AI-enabled clinical decision support and broadened general wellness policy to include certain AI-interpreted physiologic measurements, opening new integration paths if governance separates wellness from diagnostic functions.

New operating-model research shows AI scaling requires persistent cross-functional pods, embedded liaisons, and behavioral capabilities—not just technical readiness—shifting the CIO mandate toward orchestration platforms and context-graph architectures that move AI outputs into governed workflows.

On January 14–16, FDA and EMA released their first joint statement on AI in drug development, articulating 10 principles that cover human-centric design, risk-based approaches, adherence to standards, clear context of use, multidisciplinary expertise, strong data governance, robust model design, lifecycle monitoring (including data drift), and transparent communication of performance and limitations. The agencies framed AI broadly—spanning non-clinical research, clinical studies, manufacturing, and post-market surveillance—and emphasized that AI must support, not weaken, patient protections while drugs still meet core quality, efficacy, and safety requirements.

Why it matters for CIOs: This is the first transatlantic regulatory framework that explicitly sets expectations for how life sciences CIOs must architect AI lifecycle management, from design through continuous monitoring. It elevates data governance, model traceability, and documentation from IT hygiene to regulatory compliance, and assumes cross-functional governance spanning R&D, manufacturing, and quality.

Moves to consider:

Eli Lilly and NVIDIA announced a $1 billion, five-year co-innovation lab in South San Francisco at JPM 2026, combining Lilly's drug discovery expertise with NVIDIA's AI infrastructure—including a pharma-scale supercomputer, multimodal foundation models, and "agentic" wet-lab integration—to build closed-loop discovery and clinical trial models. In the same week, Servier signed large AI discovery deals with Insilico (up to $888M) and Iktos (potentially >€1B), GSK licensed Noetik's oncology foundation models for $50M, and Pfizer partnered with Boltz on biomolecular foundation models. Lilly CEO David Ricks framed the goal as transforming small-molecule discovery "from artisanal craft to scalable engineering."

Why it matters for CIOs: These moves set a new order-of-magnitude benchmark for AI infrastructure investment and validate foundation models and AI platforms as core enterprise infrastructure, not side projects. They force CIOs to confront strategic questions about build vs. buy vs. co-build, multimodal data unification (text, image, genomic, chemical), and OT/IT convergence as AI increasingly touches lab robotics, manufacturing execution systems, and clinical workflows.

Moves to consider:

Health-ISAC released its 2026 Global Health Sector Threat Landscape report on January 21–25, documenting 455 ransomware incidents targeting health organizations in 2025, with a small set of dominant groups (Qilin, INC Ransom, SAFEPAY) and supply-chain/third-party compromise as the primary attack vectors. The report, based on the Health-ISAC Ransomware Events Database and more than 1,200 targeted alerts distributed in 2025, also surveyed nearly 250 health executives and cybersecurity experts, who identified AI-enabled attacks as their top concern for 2026. Health-ISAC CSO Errol Weiss emphasized that healthcare is targeted "not due to ease of attack, but because the repercussions of disruption can be catastrophic."

Why it matters for CIOs: The report provides quantitative backing for viewing ransomware and vendor compromise as persistent, systemic risks—not outlier events—and explicitly flags AI-enhanced attacks as a near-term reality. It supports board-level conversations about sustained cyber investment, vendor risk programs, and threat-intelligence alignment specific to life sciences and healthcare ecosystems.

Moves to consider:

Munson Healthcare notified approximately 100,000 patients in mid-January about a data breach stemming from legacy Cerner (now Oracle Health) servers that were awaiting cloud migration; an unauthorized third party accessed the systems in January 2025, and Oracle Health attorneys indicated up to 80 hospitals nationally may be affected. Separately, VillageCareMAX reported a breach via TMG Health in which attackers maintained unauthorized access to a vendor system for approximately 10 months, exposing extensive PHI while internal systems remained secure. Michigan Attorney General Dana Nessel paired her consumer alert with a call to strengthen breach-notification laws.

Why it matters for CIOs: These incidents illustrate how deeply third-party and legacy-system risk can impact organizations even when core internal systems are hardened. They highlight operational gaps in vendor monitoring, post-M&A system migrations, breach-notification coordination, and business associate agreement (BAA) enforcement—all areas life sciences CIOs must tighten for their own ecosystems of CROs, CMOs, cloud vendors, and EHR/EDC providers.

Moves to consider:

On January 6, FDA updated its Clinical Decision Support guidance to expand enforcement discretion to certain AI-enabled CDS tools, including those that output a single clinically appropriate recommendation, provided they support (not replace) clinician judgment and maintain transparency regarding data inputs, underlying logic, and how recommendations are generated. The 2026 guidance places heightened emphasis on explainability and independent review to mitigate automation bias, and clarifies that software identifying patients within an indicated population for a chemotherapeutic agent (previously considered a device function) is now treated as a non-device CDS function.

Why it matters for CIOs: This revision opens new possibilities for deploying AI-driven clinical decision support without triggering full medical-device regulation—if intent, UI, and messaging stay within decision-support boundaries and tools maintain explainability. CIOs must ensure data flows, user-experience copy, and governance clearly separate decision support from diagnostic or autonomous therapeutic functions, and that CDS tools enable independent clinician review rather than black-box outputs.

Moves to consider:

In parallel with the CDS update, FDA revised its General Wellness policy on January 6 to include some non-invasive, AI-interpreted physiologic measurements—such as optical blood pressure, oxygen saturation, heart-rate variability, and glucose-related markers—as wellness products when framed strictly for wellness purposes, not diagnosis or treatment decisions. Experts noted the guidance was issued without the usual public comment period and leaves open questions about how patients and clinicians will navigate a growing pool of unregulated wearable data.

Why it matters for CIOs: This policy change creates new opportunities for integrating wearable and consumer-health data into clinical trials, real-world evidence programs, and patient-engagement platforms without full device oversight—provided governance, data flows, and user-facing messaging remain firmly in wellness territory. Blurring the line between wellness and diagnostic use carries regulatory and liability risk.

Moves to consider:

On January 12, FDA issued draft guidance on Bayesian methodology for primary inference in drug and biologics clinical trials, fulfilling a PDUFA VII commitment. The guidance allows Bayesian designs to combine trial data with prior information (prior clinical studies, real-world evidence, external or nonconcurrent controls) when scientifically justified, with applications including determining futility/success earlier in adaptive trials, informing dose selection, and supporting subgroup analyses. Designs must be justified through explicit success criteria, thoughtful priors, prospective operating-characteristic evaluation (often via simulation), and computational transparency suitable for regulatory review.

Why it matters for CIOs: This raises the bar for clinical data platforms and analytics environments: they must integrate external/RWD sources in a validated way, support large-scale simulation workloads, and produce transparent, reproducible statistical workflows suitable for regulatory review. It also reinforces that data governance and architecture are now directly linked to trial design flexibility and timeline reduction.

Moves to consider:

New framework research published January 22–25 distinguishes "AI-ready" organizations (clean data, working models) from "AI-actionable" ones (AI embedded into governed, GxP-compliant workflows). The analysis argues that many life sciences organizations have solid data platforms and trained models but lack an execution layer providing shared operational ontologies, workflow state management, context graphs, and controlled execution—so AI outputs stall at dashboards instead of driving controlled actions in LIMS, MES, QMS, or clinical systems.

Why it matters for CIOs: This explains why AI pilots succeed in labs but fail to scale: the architecture between data platforms and frontline workflows is missing. CIOs need to invest in orchestration platforms and context-graph architectures that allow AI recommendations to move into operational systems under governance, with full traceability of "what happened, when, under which constraints, and why."

Moves to consider:

Bain analysis [published January 11 and January 25](https://www.bain.com

Tech moves fast, but you're still playing catch-up?

That's exactly why 100K+ engineers working at Google, Meta, and Apple read The Code twice a week.

Here's what you get:

All delivered twice a week in just 2 short emails.

Join 100K+ engineers